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The objectives of the present study were to evaluate the risks involved in the use of 
Enrofloxacin for Salmonella Enteritidis (SE) or Salmonella Heidelberg (SH) in commer-
cial poultry and determine the effects of a probiotic as an antibiotic alternative. Two 
experiments were conducted to evaluate the risks involved in the use of Enrofloxacin 
for SE or SH in commercial poultry. Experiment 1 consisted of two trials. In each trial, 
chickens were assigned to one of three groups; control + SE challenged; Enrofloxacin 
25 mg/kg + SE; and Enrofloxacin 50 mg/kg + SE. Chickens received Enrofloxacin in 
the drinking water from days 1 to 5 of age. On day 6, all groups received fresh water 
without any treatment. All chickens were orally gavaged with 107  cfu/chick of SE at 
7 days of age and euthanized on 8 days of age. In Experiment 2, turkey poults were 
assigned to one of the three groups; control + SH; probiotic + SH; and Enrofloxacin 
50 mg/kg + SH. Poults received probiotic or Enrofloxacin in the drinking water from 
days 1 to 5 of age. On day 6, poults received fresh water without any treatment. Poults 
were orally gavaged with 107 cfu/poult of SH at 7 days of age. Poults were weighed 
and humanely killed 24 h post-SH challenge to evaluate serum concentration of fluo-
rescein  isothiocyanate-dextran to evaluate intestinal permeability, metagenomics, and 
SH infection. In both trials of Experiment 1, chickens treated with Enrofloxacin were 
more susceptible to SE organ invasion and intestinal colonization when compared with 
control non-treated chickens (P < 0.05). In Experiment 2, poults treated with 50 mg/kg 
of Enrofloxacin showed an increase in body weight, however, this group also showed an 
increase in SH susceptibility, intestinal permeability, and lower proportion of Firmicutes 
and Bacteroidetes, but with control group had the highest proportion of Proteobacteria. 
By contrast, poults that received the probiotic had the highest proportion of Firmicutes 
and Bacteroidetes, but lowest Proteobacteria. The results of the present study suggest 
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that prophylactic utilization of Enrofloxacin at five times the recommended dose in poultry 
increases the susceptibility to salmonellae infections, and confirms that probiotics may 
be an effective tool in salmonellae infections.
Keywords: enrofloxacin, Salmonella, poultry, susceptibility, metagenomics
inTrODUcTiOn
Fluoroquinolones are the third generation of quinolone 
development. Nalidixic acid and pipemidic acid are examples 
of the first generation and currently have limited activity 
against Gram-negative bacteria. Fluorinated 4-quinolones 
were introduced to the market in the 1980s and were the top 
of the line antibiotics, offering a broad spectrum of activity 
and high efficacy in a wide range of infections both orally and 
parenterally (1, 2). Nevertheless, history has demonstrated that 
the extensive use of new antibiotics is eventually shadowed 
by the appearance of resistance to those chemicals that have 
become a major global problem. This was demonstrated by the 
higher incidence of salmonellae and Campylobacter infections 
worldwide, and several reports of fluoroquinolone resistance 
in clinical isolates for these and other enteric pathogens (3–7). 
Hence, the World Health Organization (WHO) published a list 
of antibiotics that should be reserved for human use only (8), 
and fluoroquinolones were among them, due to the alarming 
evidence of quinolone-resistant zoonotic pathogens. Soon after 
the publication of the WHO report, several countries banned 
the use of fluoroquinolones in animal production (9–11). With 
growing consumer and scientific pressures, the European Union 
went one step further, creating new legislations banning the use 
of all antibiotics as growth promoters as of January 2006 (12). 
However, in many countries, the indiscriminate use and misuse 
of antibiotics, including fluoroquinolones, are still a sad reality. 
Especially in countries where there is no legislation regulating 
the use of fluoroquinolones in animal agriculture and where 
there is an abundance of generic fluoroquinolones at a low cost. 
Typical management practices in those countries are to treat 
or dose healthy neonatal chickens and turkey poults with five 
times the recommended dose of Enrofloxacin for five consecu-
tive days in the drinking water. Interestingly, in those countries, 
the incidence of Salmonella spp. and Campylobacter spp. rates 
in both humans and agriculture are also high (1, 13–16). 
Therefore, the objectives of the present study were to evaluate 
and confirm the risks involved in the use of Enrofloxacin for 
Salmonella enterica serovars Enteritidis or Heidelberg in com-
mercial poultry and to determine if poultry selected probiotics 
have a prophylactic effect when birds are challenged with SE 
and SH.
MaTerials anD MeThODs
enrofloxacin
Baytril® (Bayer Health Care LLC, Mission, KS 66201, USA) 
Enrofloxacin 3.23% concentrate solution for use in chickens and 
turkeys drinking water only.
Probiotic culture
FloraMax®-B11 (Pacific Vet Group USA Inc., Fayetteville, AR 
72703, USA) is a defined probiotic culture derived from gastro-
intestinal poultry origin that contains proprietary strains of lactic 
acid bacteria (LAB), selected by their in  vitro ability to inhibit 
enteropathogens (17).
animal source
Day-of-hatch, male broiler chickens were obtained from Cobb-
Vantress (Siloam Springs, AR, USA) for Experiment 1 or male 
turkey poults from a local hatchery in Experiment 2 and were 
randomly housed in heated brooder batteries in a controlled 
age-appropriate environment. For each experiment, birds were 
provided ad  libitum access to water, and unmedicated corn–
soybean diet, meeting the nutritional requirements of poultry 
recommended by National Research Council (18), respectively. 
All animal handling procedures were in compliance with 
Institutional Animal Care and Use Committee at the University 
of Arkansas. In each experiment, a small number of chicks or 
poults (n = 10) were humanely euthanized upon arrival by CO2 
asphyxiation. Ceca-cecal tonsils (CCT), liver, and spleen were 
aseptically cultured in tetrathionate enrichment broth (Catalog 
no. 210420, Becton Dickinson, Sparks, MD, USA). Enriched sam-
ples were confirmed negative for Salmonella by streak plating the 
samples on Xylose Lysine Tergitol-4 (XLT-4, Catalog no. 223410, 
BD Difco™) selective media.
Bacterial strains and culture conditions
The challenge organism used in Experiment 1 was a poultry 
isolate of Salmonella enterica serovar Enteritidis (SE), bacterio-
phage type 13A, obtained from the USDA National Veterinary 
Services Laboratory, Ames, IA, USA. In Experiment 2, a primary 
poultry isolate of Salmonella enterica serovar Heidelberg (SH) 
isolated in our laboratory was used. Antimicrobial susceptibility 
test revealed that both isolates were sensitive to Enrofloxacin. 
Furthermore, SE and SH are resistant to 25 μg/mL of novobiocin 
(NO, catalog no.N-1628, Sigma) and were selected for resistance 
to 20 μg/mL of nalidixic acid (NA, catalog no.N-4382, Sigma) 
in our laboratory. For both experiments, 100  μL of SE or SH 
from a frozen aliquot was added to 10 mL of tryptic soy broth 
(Catalog no. 22092, Sigma) and incubated at 37°C for 8 h, and 
passed three times every 8 h to ensure that all bacteria were in 
log phase. Post-incubation, bacterial cells were washed three 
times with sterile 0.9% saline by centrifugation at 1,864 × g for 
10 min, reconstituted in saline, quantified by densitometry with 
a spectrophotometer (Spectronic 20D+, Spectronic Instruments 
Thermo Scientific), and diluted to an approximate concentration 
of 108 cfu/milliliter. Concentrations of SE or SH were further veri-
fied by serial dilution and plating on brilliant green agar (BGA, 
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Catalog no. 70134, Sigma) with NO and NA for enumeration of 
actual cfu used to challenge the chickens and turkeys.
experimental Design in  
chickens and Turkeys
Evaluation of Enrofloxacin in Neonatal Chickens 
Challenged with Salmonella Enteritidis. Experiment 1
Two independent trials were conducted. In each trial, 36 chickens 
were randomly assigned to one of three groups (n = 12): control 
SE challenged without Enrofloxacin; Enrofloxacin 25  mg/kg SE 
challenged; and Enrofloxacin 50 mg/kg SE challenged. Chickens 
received Enrofloxacin from days 1 to 5 of age in the drinking water. 
At day 6, treated groups received fresh water without any treat-
ment. Fresh water without antibiotic was administered to control 
chickens throughout the experiment. All chickens were orally 
gavaged with 107 cfu/chick of SE at 7 days of age. Chickens were 
humanely euthanized for culture at 8 days of age as describe below.
Salmonella Recovery
At 8 days, broilers were humanely euthanized and liver and spleen 
were collected aseptically and enriched in 10 mL of tetrathionate 
broth (Becton Dickinson) overnight at 37°C. Following enrich-
ment, each sample was streaked for isolation on BGA plates 
containing 25 μg/mL of NO and 20 μg/mL of NA. The plates 
were incubated at 37°C for 24 h and examined for the presence or 
absence of antibiotic-resistant SE. CCT were collected aseptically, 
homogenized within sterile sample bags (Nasco, Fort Atkinson, 
WI, USA) using a rubber mallet and diluted with saline (1:4 by 
wt/vol) and 10-fold dilutions were plated on BGA with NO and 
NA, incubated at 37°C for 24  h to enumerate total SE colony 
forming units. The CCT samples were enriched in 2× concen-
trated tetrathionate enrichment broth and further incubated at 
37°C for 24 h to enrich. Following this, enrichment samples were 
plated on BGA with NO and NA and incubated at 37°C for 24 h 
to confirm presence/absence of typical lactose-negative colonies 
of Salmonella.
Evaluation of Prophylactic Administration of 
FloraMax-B11® Enrofloxacin in Neonatal Turkey 
Poults Challenged with Salmonella Heidelberg. 
Experiment 2
In Experiment 2, 72 day-of-hatch turkey poults were neck 
tagged, weighed, and randomly assigned to one of the three 
groups (n =  24/group): control SH challenged without treat-
ment; probiotic SH challenged; and Enrofloxacin 50 mg/kg SH 
challenged. Poults received FloraMax-B11® or Enrofloxacin from 
days 1 to 5 of age in the drinking water. Control group received 
fresh water without any treatment throughout the duration of the 
experiment. At day 6, treated groups received water without any 
treatment. All poults were orally gavaged with 107 cfu/poult of SH 
at 7 days of age. Poults were weighed and humanely euthanized 
24 h post-SH challenge (day 8 of age) to evaluate serum concen-
tration of fluorescein isothiocyanate-dextran (FITC-D) and cecal 
bacterial community compositions as describe below, as well as 
Salmonella recovery and plating from CCT as was previously 
described. Samples from CCT were also plated in Man Rogosa 
Sharpe (Difco™ Lactobacilli MRS Agar VWR Cat. No. 90004-
084 Suwanee, GA 30024) to evaluate total number of LAB.
Serum Determination of FITC-D Leakage
Intestinal leakage of FITC-D (MW 3–5 KDa; Sigma-Aldrich Co., 
St. Louis, MO, USA) and the measurement of its serum concen-
tration were done in experiment 2 as a marker of paracellular 
transport and mucosal barrier dysfunction (19–22). At 24 h, post-
SH challenge (day 8 of age), poults in all groups were given an oral 
gavage dose of FITC-D (4.16 mg/kg). Following 2.5 h, they were 
killed by CO2 asphyxiation. Blood samples were collected from 
the femoral vein kept at room temperature for 3 h and centrifuged 
(500 × g for 15 min) to separate the serum from the red blood 
cells. FITC-D levels of diluted serum samples (1:5 PBS) were 
measured at excitation wavelength of 485 nm and an emission 
wavelength of 528 nm with a Synergy HT, Multi-mode microplate 
fluorescence reader (BioTek Instruments, Inc., Vermont, USA). 
Fluorescence measured was then compared to a standard curve 
with known FITC-D concentrations. Gut leakage for each bird 
was reported as microgram of FITC-D/mL of serum (20).
DNA Extraction and Illumina-Based Analysis of Microbial 
Community Diversity
Cecal content from six poults was obtained, homogenized 
thoroughly in four volumes diluent (0.85% NaCl, 0.1% peptone), 
centrifuged at 300 ×  g for 2  min to remove large debris, and 
finally, 0.5 mL of aliquots (average 8 mg dry weight) were pelleted 
at 10,000 × g for 5 min. Extraction of DNA was performed imme-
diately using the QIAamp DNA Stool Mini Kit (QIAGEN, Hilden, 
Germany). Bacterial community compositions at Phylum and 
Class level were performed using Illumina dye sequencing (Era7 
Bioinformatics Inc., Cambridge, MA 02142, USA). The analysis 
corresponded to 16S rRNA amplicons from V6 region sequenced 
with Illumina technology (23). Reads were assigned to a taxon 
based on sequence similarity to 16S rRNA genes extracted from 
the NCBI nt database. The 16S rRNA sequences were extracted 
from NCBI based on their presence in the set of sequences 
included in the Ribosomal Database Project (RDP) (24) and on 
the specificity of their taxonomical assignment based on the low-
est common ancestor (LCA) approach adopted metagenomics 
analysis as the last version of Meta-Genome Analyzer (MEGAN). 
The algorithm was similar to the assignment algorithm adopted 
by MEGAN tool (25). Phylum distribution in all the samples is 
expressed in % on the total merged reads of each sample.
Data and statistical analysis
Log10 cfu/g of SE and SH in cecal contents, body weight (BW), 
body weight gain (BWG), serum FITC-D concentration, and 
proportion of bacterial composition were subjected to analysis of 
variance as a completely randomized design, using the General 
Linear Models procedure of SAS (26). Significant differences 
among the means were determined by Duncan’s multiple-range 
test at P <  0.05. Enrichment data were expressed as positive/
total chickens (%), and the percent recovery of SE and SH was 
compared using the chi-squared test of independence, testing all 
possible combinations to determine the significance (P ≤ 0.05) 
for these studies (27).
TaBle 3 | evaluation of prophylactic administration of FloraMax-B11® or enrofloxacin on body weight, body weight gain, and serum concentration of 
FiTc-Da in neonatal turkey poults.
Body weight (grams) Body weight gain (grams) serum FiTc-D (μg/ml)
Control SH 105.59 ± 2.31c 51.14 ± 2.45c 1.24 ± 0.08c
FloraMax-B11® + SH 106.54 ± 2.24c 52.15 ± 2.39c 0.23 ± 0.06c
Enrofloxacin 50 mg/kg + SH 120.57 ± 2.60b 63.87 ± 2.71b 7.28 ± 3.09b
Experiment 2.
aPoults received FloraMax-B11® or Enrofloxacin from days 1 to 5 of age in the drinking water. At day 6, all groups received fresh water without any treatment. All poults were orally 
gavaged with 107 cfu/poult of SH at 7 days of age. FITC-D was administered on 8 days of age.
b,cSuperscripts within columns indicate significant difference at P < 0.05, n = 24.
TaBle 2 | evaluation of prophylactic administration of FloraMax-B11® or enrofloxacin on organ invasion and cecal colonization of Salmonella 
heidelberg (sh)a in neonatal turkey poults.
liver and spleenb cecal tonsilsb log10 sh/g of ccTc log10 lactic acid bacteria/g of ccTc
Control SH 2/24 (8.33%)d 5/24 (20.83%)d 0.66 ± 0.29d 6.67 ± 0.26d
FloraMax-B11® + SH 0/24 (0%)d 0/24 (0%)e 0.0 ± 0.0e 7.16 ± 0.24d
Enrofloxacin 50 mg/kg + SH 0/24 (0%)d 8/24 (33.33%)d 1.95 ± 0.28d 4.06 ± 0.22e
Experiment 2.
aPoults received FloraMax-B11® or Enrofloxacin from days 1 to 5 of age in the drinking water. At day 6, all groups received fresh water without any treatment. All poults were orally 
gavaged with 107 cfu/poult of SH at 7 days of age. Poults were humanely killed for culture at 8 days of age.
bData of liver and spleen as well as cecal tonsils is expressed as positive/total poults (%).
cLog 10/g of ceca-cecal tonsil (CCT) data is expressed as mean ± SD, n = 12.
d,eSuperscripts within columns indicate significant difference at P < 0.05.
TaBle 1 | evaluation of enrofloxacin in neonatal chickens challenged 
with Salmonella enteritidis (se)a 24 h after antibiotic treatment on organ 
invasion and cecal colonization.
liver and 
spleenb
log 10  
se g/ccTc
cecal  
tonsilsb
Trial 1
Control + SE 0/12 (0%)e 1.23 ± 0.45e 5/12 (41.7%)e
Enrofloxacin 25 mg/kg + SE 4/12 (33.3%)d 2.01 ± 0.66e 6/12 (50%)e
Enrofloxacin 50 mg/kg + SE 5/12 (41.7%)d 4.46 ± 0.37d 12/12 (100%)d
Trial 2
Control + SE 0/12 (0%)e 1.23 ± 0.45e 5/12 (41.7%)e
Enrofloxacin 25 mg/kg + SE 4/12 (33.3%)d 2.01 ± 0.66e 6/12 (50%)e
Enrofloxacin 50 mg/kg + SE 5/12 (41.7%)d 4.46 ± 0.37d 12/12 (100%)d
Experiment 1.
aChickens received Enrofloxacin from days 1 to 5 of age in the drinking water. At day 6, 
all groups received fresh water without any treatment. All chickens were orally gavaged 
with 107 cfu/chick of SE at 7 days of age. Chickens were humanely killed for culture at 
8 days of age.
bData of liver and spleen or ceca-cecal tonsils is expressed as positive/total chickens (%).
cLog 10 SE/g of ceca-ceca tonsils (CCT) data is expressed as mean ± SD.
d,eSuperscripts within columns indicate significant difference at P < 0.05.
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resUlTs
The results from experiment 1, evaluating the effect of 
Enrofloxacin on neonatal chickens challenged with SE 24 h after 
antibiotic treatment on organ invasion and cecal colonization, 
are summarized in Table  1. In trial 1, there was a significant 
(P < 0.05) increase in the incidence of SE in liver and spleen in 
chickens treated with either 25 or 50 mg/kg of Enrofloxacin when 
compared with control chickens. Furthermore, chickens treated 
with 50  mg/kg of Enrofloxacin showed a 3.23 log increased in 
the incidence of SE in CCT as well as total cfu of SE/gram of 
ceca content when compared with control chickens and 0.45 log 
increase when compared with chickens treated with 25  mg/kg 
of Enrofloxacin. Similar results were observed in trial 2, where 
chickens treated with both doses of Enrofloxacin showed an 
increase in SE incidence in CCT as well as total numbers of SE 
in the cecal content when compared with control non-treated 
chickens (Table 1).
The results from experiment 2 evaluating the prophylactic 
administration of FloraMax-B11® or Enrofloxacin on organ inva-
sion and cecal colonization of SH in neonatal turkey poults are 
summarized in Table 2. No significant differences were observed 
in the SH organ invasion between treated or control groups 
(P > 0.05), nevertheless, poults treated with the probiotic showed 
a significant reduction in both incidence of SH in CCT and total 
numbers of SH in ceca content when compared with poults 
treated with 50  mg/kg of Enrofloxacin or control non-treated 
poults (P  <  0.05). Enrofloxacin poults also had a significant 
reduction in the total numbers of LAB (Table 2).
The results of the evaluation of prophylactic administration of 
FloraMax-B11® or Enrofloxacin on BW, BWG, and serum con-
centration of FITC-D in neonatal turkey poults in Experiment 
2 are summarized in Table  3. Poults treated with 50  mg/kg of 
Enrofloxacin showed a significant increase in BW and BWG 
when compared with probiotic or control non-treated poults. 
Interestingly, poults in this group also showed a significant 
increase in gut permeability (Table 3).
Table  4 shows the results of the Phylum distribution 
(cumulative% LCA) and class direct assignment in % for all 
ceca samples of turkey poults following prophylactic adminis-
tration of FloraMax-B11® or Enrofloxacin in Experiment 2. At 
the phylum level microbiome analysis, poults treated with the 
probiotic had the higher proportion of Firmicutes, followed by 
control poults and poults treated with Enrofloxacin. A significant 
reduction was observed in Bacteroidetes in poults treated with 
TaBle 4 | Phylum distribution (cumulative% lowest common ancestor) 
and class direct assignment in % for all ceca samples of turkey poults 
following prophylactic administration of FloraMax-B11® or enrofloxacin.
control + sh FloraMax- 
B11® + sh
enrofloxacin 
50 mg/kg + sh
Phylum
Firmicutes 42 ± 10b 55 ± 8a 9 ± 4c
Bacteroidetes 19 ± 6a 23 ± 4a 10 ± 2b
Proteobacteria 29 ± 4a 18 ± 5b 31 ± 3a
class
Gammaproteobacteria 15.07 ± 2.58a 6.16 ± 0.083b 24.95 ± 2.76a
Clostridia 5.01 ± 2.22a 4.25 ± 1.30a 2.40 ± 0.04b
Bacilli 3.05 ± 0.01a 4.21 ± 0.01a 1.11 ± 0.06b
Experiment 2.
a,bSuperscripts within rows indicate significant difference at P < 0.05, n = 6.
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the antibiotic. Furthermore, significant increases in the propor-
tion of Proteobacteria were observed in poults that received 
Enrofloxacin or control poults when compared with poults that 
received FloraMax-B11®. At the class level, it was interesting 
to observe that both control and Enrofloxacin poults had an 
increase in Gammaproteobacteria, but Clostridia and Bacilli were 
decreased in Enrofloxacin birds when compared with control or 
poults treated with the probiotic (Table 4).
DiscUssiOn
Considerable scientific evidence has shown that the use of certain 
antibiotics increases enteric colonization of antibiotic-resistant 
strains of enteric pathogens in domestic animals (28–32). 
Because some of these pathogens are extremely resistant to many 
antibiotics and are capable of rapidly developing resistance when 
exposed (7, 13, 14), antibiotic prophylaxis or treatment has been 
reported to actually increase the occurrence and severity of these 
infections in commercial poultry (33, 34). In addition, the lack 
of effect of these antibiotics in resistant enteropathogens, some 
researchers have shown that antibiotics can actually cause dis-
ruption in the microbiome (35), accompanied with reduction of 
short chain fatty acids (36, 37) and increased luminal pH in the 
distal gastrointestinal tract (38). In the present study, we evaluate 
the management practice in certain countries of using five times 
the recommended dose of Enrofloxacin in neonatal chickens and 
turkey poults for five consecutive days after placement, and look 
at their susceptibility to salmonellae infections 24 h after treat-
ment. In trial 1 of Experiment 1, chickens treated with either 25 
or 50 mg/kg of Enrofloxacin were more susceptible to SE organ 
invasion when compared with control non-treated chickens. In 
addition, chickens treated with 50 mg/kg of Enrofloxacin in trial 
1 and both Enrofloxacin doses in trial 2 had a significant increase 
in total SE cfu in cecae when compared with control chickens, 
suggesting that this management practice performed in poor 
antimicrobial stewardship countries, increased susceptibility to 
SE infections in broiler chickens.
Salmonella Heidelberg is among the top three Salmonella 
serovars isolated from humans when poultry products were 
linked to the infection (39–42). Furthermore, SH resistant to 
various antimicrobial agents has been isolated from domestic 
animals (43–45). In Experiment 2, our results are in agree-
ment with previous publications from our laboratory, showing 
not only the low invasiveness of SH for internal organs, but 
also effectiveness of FloraMax-B11® in reducing SH intestinal 
colonization in turkey poults (46). Published studies have also 
shown that FloraMax®-B11 increased colonization resistance to 
Salmonella spp. infections (47–51), reduces idiopathic diarrhea 
in commercial turkey brooding houses (52), as well as increased 
performance and reduced costs in poultry production (53, 54). 
In the present study, it was remarkable to observe that poults 
treated with 50  mg/kg of Enrofloxacin were more susceptible 
to SH colonization and that this effect was associated with a 
significant reduction in the total number of LAB. Poults treated 
with 50 mg/kg of Enrofloxacin showed a significant increase in 
BW and BWG, however, this group also showed a significant 
increase in gut permeability. Metagenomic analysis of cecal 
content using the MEGAN software can be used to interactively 
analyze and compare metagenomic and metatranscriptomic 
data, thereby providing a percent identity filter that can be used 
to enforce the following levels of percentage sequence identities 
for an assignment at a given taxonomic level (25). In Experiment 
2, poults treated with Enrofloxacin had a lower proportion of 
Firmicutes and Bacteroidetes, suggesting that the broad spec-
trum of Enrofloxacin had a profound impact upon the micro-
biome. Interestingly, these poults had the highest proportion of 
Proteobacteria (similar to control). Such a high dose of antibiotic 
also had a significant increase in Gammaproteobacteria. Changes 
in the proportion of phylum and class were associated with higher 
SH intestinal colonization since Salmonella belongs to phylum 
Proteobacteria, class Gammaproteobacteria. Furthermore, poults 
treated with Enrofloxacin had lower proportions of Clostridia 
and Bacilli when compared with control or probiotic poults. 
Antibiotics administered in low doses have been widely used as 
growth promoters in poultry for over half a century. However, the 
exact mechanisms for this effect are elusive. Similarly, there are 
no reports that have described the impact of Enrofloxacin at low 
or high therapeutic dose on the microbiome or metabolomics in 
poultry. This is the first report that describes profound changes 
in microbiome of turkey poults that received a high dose of 
Enrofloxacin, shifting it and making them more susceptible to a 
SH experimental challenge.
By contrast, poults that received the probiotic had the high-
est proportion of Firmicutes and Bacteroidetes, but the lowest 
amount of Proteobacteria. These birds also showed significant 
reduction in Gammaproteobacteria, but similar to the control 
group, a higher proportion in Clostridia and Bacilli. The shift 
in these bacterial populations had a positive effect on reducing 
SH colonization following challenge and confirms our previous 
research (46).
The results of these experiments suggest that, five times the 
recommended dose of Enrofloxacin, a broad-spectrum antibi-
otic can have a negative effect on the microbiome that may be 
responsible for an enhancement of SH colonization, which has 
been previously demonstrated with other enteropathogens (4, 
28, 29, 31, 32). The mechanism of antibiotic-altered resistance 
was not investigated in the present study. However, regardless 
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of the mechanism involved, increased susceptibility of turkey 
poults to Salmonella was observed in two experiments following 
Enrofloxacin treatment. Furthermore, based on the microbiota 
changes following fluoroquinolone administration, including 
the increase in Proteobacteria, these results suggest that this 
practice may predispose to other infectious diseases that will 
further require the use of additional antibiotics and broaden the 
selection of antimicrobial resistance. Acquisition of resistance 
to fluoroquinolones has been reported to be a multifaceted 
process, which includes spontaneous point mutations that result 
in amino acid substitutions within the topoisomerase subunits 
GyrA, GyrB, ParC, or ParE, reduced expression of outer mem-
brane porins, overexpression of multidrug efflux pumps, and/or 
plasmid-mediated quinolone resistance (1, 2, 7, 13, 15, 55, 56). It 
is remarkable to contemplate that the alarming incidence of cer-
tain enteric pathogens is associated with the indiscriminate use of 
some antibiotics in animal agriculture in some countries (42, 45, 
57–61). Since poultry products have been identified as important 
reservoirs of human infections, this is a growing public health 
concern. Given that fluoroquinolones and other antibiotics are 
over used in animal production, any effort to diminish the risk of 
resistance is crucial. The results of the present study and of previ-
ous investigations involving antibiotics and other enteropatho-
gens suggest that prophylactic utilization of some antibiotics in 
poultry increase the susceptibility to salmonellae colonization 
and organ invasion. Therefore, antibiotics should be limited to 
infections of specific bacteria with known antibiotic sensitivity. 
In addition, our findings also confirm previous studies suggesting 
that the use of alternatives, such as probiotics, can be an effective 
tool in controlling salmonellae infections.
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